Zuellig pledges to invest over S$50m in S'pore centre
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
ZUELLIG Pharma plans to work with Singapore's National Healthcare Group to develop predictive models for early health screening, and carry out treatment cost versus quality analysis, using data analytics. It announced this on Wednesday, following an investment commitment of more than S$50 million over the next five years in its new Singapore-based innovation centre.
The centre, known as Zuellig Health Solutions (ZHS), will develop data, digital and disease management solutions. These are meant to help doctors develop more effective treatment plans, support patients managing chronic conditions, and help payors manage healthcare costs, it said.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
OCBC is said to emerge as lead bidder for HSBC Indonesia assets
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
